

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY DCKET NO. 01994-0024	SERIAL NO. 08/966,940	FILING DATE November 10, 1997
APPLICANT Lawrence Tamarkin et al.		GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	DA	4,197,237	4/8/80	Leute et al.	260	112	
	DB	4,197,286	4/8/90	Rao	424	1	
	DC	4,213,964	7/22/80	Buckler	424	85	
	DD	4,215,036	7/29/80	Malley	260	112	
	DE	4,218,436	8/19/80	Fitzpatrick	424	85	
	DF	4,329,281	5/11/82	Christenson et al.	260	112	
	DG	4,332,787	6/1/82	Homcy et al.	424	1	
	DH	4,346,074	8/24/82	Gilmour et al.	424	92	
	DI	4,487,780	12/11/84	Scheinberg	424	294	
	DJ	4,578,270	3/25/86	Csizer et al.	424	92	
	DK	4,608,252	8/26/86	Khanna et al.	424	85	
✓	DL	4,639,336	1/27/87	Jouquey et al.	260	397	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO
	DM						
	DN						
	DO						
	DP						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	DR	✓	Kirchner et al., "The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2", <i>Cancer</i> , No. 7, Vol. 67, pages 1862-1864 (1991).
PM	DS	✓	Tomii et al., "Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier", <i>Jpn. J. Med. Sci. Biol.</i> Vol. 44, pages 75-80 (1991).

EXAMINER Prema Menz	DATE CONSIDERED 1/28/99
-------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

DOCKET NO.

SERIAL NO.

FILING DATE

01/20/98
C544 U.S.
P
01/24-0024

08/966,940

November 10, 1997

APPLICANT

GROUP

Lawrence Tamarkin et al.

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	AA	4,740,589	04/26/88	Moreno	530	395	
	AB	3,145,144	08/18/64	Ando	167	78	
	AC	3,269,912	08/30/66	Grase	167	78	
	AD	3,577,523	05/04/71	Stolar et al.	424	88	
	AE	4,069,313	01/17/78	Woodhour et al.	424	89	
	AF	3,983,228	09/28/76	Woodhour et al.	424	89	
	AG	3,531,565	09/29/70	Webb et al.	424	92	
	AH	3,149,036	09/15/64	Woodhour et al.	167	78	
	AI	3,399,263	08/27/68	Strazdins et al.	424	88	
	AJ	4,657,763	04/14/87	Finkelstein	424	131	
↓	AK	4,330,530	05/18/82	Baker	424	131	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
PM	AL	WO 91 02078	2/21/91	PCT		
	AM	0 156 242 ✓	12/3/85	Europe		
	AN	0 269 408 ✓	24/11/87	Europe		
DeMS	AO	2 334 366 ✓	7/19767	France		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM	AP	Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," <i>The Journal of Experimental Medicine</i> , Vol. 170, pages 1015-1020 (1989) ✓
	AR	Lanzavecchia, "Identifying Strategies for Immune Intervention," <i>Science</i> , Vol. 260, pages 937-944 (1993)
	AS	Paciotti, et al., "Interleukin 2 differentially effects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line <i>in vitro</i> and <i>in vivo</i> ," <i>Anti-Cancer Research</i> , Vol. 8, pages 1233-1240 (1988)
↓	AT	Paciotti, et al., "Interleukin 1 differentially synchronizes estrogen dependent and estrogen-independent human breast cells in G0/G1 phase of the cell cycle," <i>Anti-Cancer Research</i> , vol. 11, pages 25-32 (1991)

EXAMINER

Prema Nent


DATE CONSIDERED

1/28/97

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

BULKY CHECK NO.  01999-0024	SERIAL NO. 08/966,940	FILING DATE November 10, 1997
APPLICANT Lawrence Tamarkin et al.		GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PM	BA	4,339,437	07/13/82	Rosenberg et al.	424	131	
	BB	4,177,263	12/04/79	Rosenberg et al.	424	131	
	BC	4,053,587	10/11/77	Davidson et al.	424	131	
	BD	4,977,286	12/11/90	Nicolaou et al.	552	4	
	BE	5,017,687	05/21/91	Vahlne et al.	530	324	
perms	BF	4,812,556	04/14/89	Vahlne et al.	530	324	
	BG	4,880,750	11/14/89	Francoeur	436	501	
	BH	5,035,995	07/30/91	Taguchi et al.	435	4	
	BI	4,882,423	11/21/89	Taguchi et al.	530	380	
	BJ	4,906,564	03/06/90	Lyon et al.	435	7	
✓	BK	5,019,497	05/28/91	Olsson	435	7.23	

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION	
						YES	NO.
PM	BL	2 533 827 ✓	30/9/82	France			
PM	BM	981,242 ✓	1/20/65	England			
	BN						
	BO						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PM ↓	BP	✓	Paciotti, et al., "Interleukin 1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro," <i>Mol. Endocrinol.</i> , Vol. 2, pages 459-464 (1988)
	BR	✓	Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chloropheniramine-induced Phospholipidosis," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 37, No. 2, pages 139-147 (1989)
	BS	✓	Hashimoto et al., "Action Site of Circulating Interleukin-1 on the Rabbit Brain," <i>Brain Research</i> , Vol. 540, pages 217-223 (1991)
	BT		Ohmann et al., "Expresion of Tumor Necrosis Factor- α Receptors on Bovine Macrophaes, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," <i>Lymphokine Research</i> , Vol. 9, No. 1, pages 43-58 (1990)

EXAMINER	PREMA MINT	DATE CONSIDERED	1/28/99
----------	------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.